The COVID-19 vaccine market is expected to be valued at $10 billion a year across developed countries based on analyst estimates from Morgan Stanley and Credit Suisse. An analyst from Credit Suisse even expects that the market could be worth more than $10 billion in the United States alone. In recent news, vaccine candidates from Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca have shown high efficacy rates, with Pfizer leading the pack as it obtained approval from the UK and Canada for mass rollout. The COVID-19 vaccine race might be already declaring its frontrunners in the coming months, and we deem it necessary to look at the patent landscape these pharma giants are operating in.